近日，上海交通大學(xué)藥學(xué)院賈偉教授等撰寫的學(xué)術(shù)論文——Gut microbiota：a potential new territory for drug targeting發(fā)表于國(guó)際著名學(xué)術(shù)期刊《自然—藥物開發(fā)評(píng)論》（Nature Reviews Drug Discovery,，NRDD）上。NRDD作為Nature 雜志子刊物,，是國(guó)際藥學(xué)領(lǐng)域頂級(jí)學(xué)術(shù)期刊之一。目前該雜志的影響因子為20.97,。
作者在該文中從系統(tǒng)生物學(xué)的角度闡釋了腸道微生態(tài)系統(tǒng)作為潛在的藥物治療靶點(diǎn)的可能性,，并重點(diǎn)提出了基于腸道菌群的藥物治療策略和可能的干預(yù)模式。
在生命科學(xué)中,，腸道菌群一直被認(rèn)為廣泛地參與了宿主營(yíng)養(yǎng)吸收,、腸道與免疫系統(tǒng)的發(fā)育等重要的生理過程，其變化與多種疾病的發(fā)生,、發(fā)展和轉(zhuǎn)歸密切相關(guān),。然而，極其復(fù)雜的腸道微生態(tài)系統(tǒng)與研究技術(shù)手段的局限性，始終束縛著人類對(duì)腸道微生態(tài)系統(tǒng)的認(rèn)識(shí),。近年來，不斷發(fā)展的各種組學(xué)技術(shù),，如代謝組學(xué),、元基因組學(xué)與分子生物學(xué)技術(shù)等一起為揭開腸道菌群的神秘面紗提供了可能的技術(shù)支撐。上海交通大學(xué)藥學(xué)院和系統(tǒng)生物醫(yī)學(xué)研究院采用代謝組學(xué)和元基因組學(xué),，開展系統(tǒng)生物學(xué)研究近年來在國(guó)際上非?；钴S。該論文的發(fā)表將在代謝性疾病發(fā)病機(jī)制,、藥理學(xué),、天然產(chǎn)物活性評(píng)價(jià)等學(xué)術(shù)領(lǐng)域產(chǎn)生深遠(yuǎn)的影響。
生物谷推薦原始出處：
Nature Reviews Drug Discovery 7, 123-129 (February 2008) | doi:10.1038/nrd2505
Opinion: Gut microbiota: a potential new territory for drug targeting
Wei Jia1, Houkai Li1, Liping Zhao1 & Jeremy K. Nicholson2 About the authors
Abstract
The significant involvement of the gut microbiota in human health and disease suggests that manipulation of commensal microbial composition through combinations of antibiotics, probiotics and prebiotics could be a novel therapeutic approach. A systems perspective is needed to help understand the complex host–bacteria interactions and their association with pathophysiological phenotypes so that alterations in the composition of the gut microbiota in disease states can be reversed. In this article, we describe the therapeutic rationale and potential for targeting the gut microbiota, and discuss strategies and systems-oriented technologies for achieving this goal.
Author affiliations
Wei Jia, Haukai Li and Liping Zhao are at the School of Pharmacy and at the Institute for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China.
Jeremy K. Nicholson is at the Department of Biomolecular Medicine, Division of Surgery Oncology Reproductive Biology and Anaesthetics, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK
Correspondence to: Wei Jia1 Email: [email protected].
